A glycan biological age report gives you one headline number and a set of indexes underneath it. The indexes are where the information is. The headline number is a model output derived from them, and reading it without the underlying traits tends to produce either false alarm or false reassurance.
This page covers what each index measures, how reproducible the measurement is, what moves it, and the question most reports leave unanswered: how long you would have to wait before a second test could tell you anything.
The Verdict
What the test actually measures
Immunoglobulin G is the main circulating antibody, and every IgG molecule carries a branched sugar structure attached to its constant region. That structure is not decorative. It determines whether the antibody drives an inflammatory response or dampens one, and its composition shifts predictably across the lifespan.
Laboratories separate these structures by capillary gel electrophoresis with laser-induced fluorescence, which resolves the glycan pool into individual peaks. The peaks are then grouped into the traits that appear on your report. The biological rationale is well established: the age-associated shift toward agalactosylated IgG has been reproduced across large population studies and is one of the more robust findings in the ageing biomarker literature. GlycanAge, the main commercial provider of the test, publishes the underlying research base.
| Index | What it is | How it behaves with age | Weight |
|---|---|---|---|
| G0, agalactosylated glycans | IgG antibodies carrying no terminal galactose | Rises with age. The single strongest age-associated glycan trait, and the one most closely tied to a pro-inflammatory antibody state | Primary |
| G2, digalactosylated glycans | IgG carrying galactose on both arms | Falls with age. Associated with the anti-inflammatory end of antibody function | Primary |
| G1, monogalactosylated glycans | One galactose present | Sits between G0 and G2 and moves less decisively than either | Supportive |
| S, sialylation | Terminal sialic acid on the glycan structure | Falls modestly with age. Sialylated IgG is associated with reduced inflammatory signalling | Supportive |
| B, bisecting GlcNAc | A branching sugar added to the core structure | Rises with age. Contributes to the composite but carries less independent signal | Supportive |
| F, fucosylation | Core fucose on the glycan | Barely moves with age. Reported for completeness and as an assay quality check | Supportive |
How precise is the measurement
Unusually for a consumer biological age test, this has been studied directly. A precision study of the glycan clock of ageing reported coefficients of variation below 10% for 23 of 27 individual glycan peaks, and below 3% for all the derived traits that appear on reports. G0 reproduced to within 1.24 to 1.59%. Fucosylation was the most reproducible at 0.21 to 0.28%, and sialylation the least at 2.24 to 2.75%.
Those are good numbers, and they are better than the reproducibility of several widely used clinical assays. The uncertainty in a glycan result does not come from the laboratory.
| What was measured | Finding | What it means for reading your result |
|---|---|---|
| Analytical precision of the assay | Derived glycan traits show coefficients of variation under 3%. G0 sits at 1.24–1.59%. Fucosylation is the most reproducible at 0.21–0.28%, sialylation the least at 2.24–2.75% | The measurement itself is reliable. This is not where the uncertainty lives |
| Change over 90 days, young men | No statistically significant change in any trait | Three months is not enough time for age-related drift to appear |
| Change over 12 weeks, young women | G2 and fucosylation rose, G0 fell, attributed to menstrual cycle effects. Described as minimal | Cycle phase is a real source of movement in women over exactly the window most retest schedules use |
| Change over 5 years | G0 rose roughly 15%. Sialylation and G2 fell roughly 10.5% | Age-related drift runs at roughly 3% a year in the strongest marker |
| Change over 10 years | Same direction, G0 and bisecting GlcNAc up, G2 and sialylation down | The trajectory is consistent and slow |
The retest interval question
Put the two halves of that table together and a practical rule falls out. The assay reproduces to within roughly 1 to 3%. Age-related drift in the strongest trait runs at roughly 3% a year. A three-month interval therefore covers about 0.75% of expected biological change, against a measurement uncertainty several times larger.
This is the single most useful thing to understand before buying a retest, and it is not a criticism of the technology. It follows from the biology being genuinely slow. A difference between two tests taken three months apart is dominated by short-term inflammatory state, assay variation, and in women by cycle phase, rather than by any change in ageing trajectory.
Across the biological age products we assess on a single rubric, retest cadence is where the gap between the marketing and the measurement science is widest. Three-month retest bundles are common across the category, and the underlying longitudinal data supporting a detectable change at that interval is not there for any of the clock families. If you retest, a year is a more defensible interval, and holding the draw to a consistent point in the cycle removes one known source of movement.
What drives a high result
| Driver | What the evidence shows | How to read it |
|---|---|---|
| Sex hormones | Estrogen strongly influences IgG galactosylation. Glycan age shifts across the menopausal transition, and hormone therapy moves it | The largest single non-age driver in women. A result taken mid-transition reflects hormonal state as much as accumulated ageing |
| Chronic inflammatory load | The trait the composite is built to capture. Autoimmune disease, active infection, and inflammatory conditions all push G0 up | Check hsCRP alongside. An elevated glycan age with a raised hsCRP is a different finding from one with a normal hsCRP |
| Adiposity and metabolic state | Higher BMI, insulin resistance, and adverse lipids associate with a higher glycan age | Overlaps substantially with what a standard metabolic panel already tells you |
| Smoking and alcohol | Both associate with an older glycan profile | Established in population data rather than in intervention trials |
| Genetics | The glycan clock is substantially heritable | Part of your result is a starting point you did not choose and will not move |
The hormonal driver deserves particular attention because it is large and frequently unaccounted for. Estrogen influences IgG galactosylation directly, glycan age shifts across the menopausal transition, and hormone therapy moves it. A woman testing in perimenopause is measuring a hormonal state alongside an ageing signal, and the two cannot be separated in a single result. Our perimenopause panel covers the markers that do separate them.
What to do with the result
- Read it alongside an inflammatory and metabolic panel. hsCRP, fasting insulin, HbA1c and a lipid panel identify an actionable driver far more often than the glycan report does.
- Investigate a genuinely discordant result. A markedly elevated glycan age with a normal hsCRP and normal metabolic markers is worth a clinical conversation, since undiagnosed autoimmune and inflammatory conditions sit in that space.
- Do not treat the number as a target. There is no threshold, no guideline, and no outcome trial showing that moving an index changes what happens to you.
- Choose a retest interval that matches the biology. A year is interpretable. Three months mostly is not.
- Act on the drivers, not the score. The interventions associated with a lower glycan age in observational data are the same ones that move standard markers, and those have outcome evidence behind them.
For how this test family compares with the alternatives, see methylation clock vs immune age and our rubric-scored best biological age test comparison.
Frequently Asked Questions
What does the biological age number on a glycan test mean?
It is a model output, not a measurement of your body. The laboratory measures the relative abundance of glycan structures on your IgG antibodies, and a model trained on population data converts that pattern into the chronological age at which it would be typical. A glycan age of 47 means your antibody glycosylation pattern resembles the population average at 47. It does not mean your organs, your cells, or your cardiovascular risk correspond to a 47-year-old.
What are the five glycan indexes and what does each measure?
They are groupings of IgG glycan structures. G0 counts antibodies with no terminal galactose and rises with age, making it the strongest single age signal and the one associated with a pro-inflammatory antibody state. G2 counts fully galactosylated antibodies and falls with age. G1 sits between the two. Sialylation, the presence of terminal sialic acid, falls modestly with age and associates with reduced inflammatory signalling. Bisecting GlcNAc, a branching structure, rises with age. Fucosylation is reported but barely changes with age.
What is the difference between primary and supportive indexes?
Primary indexes carry most of the weight in the composite and move most decisively with age, which in practice means G0 and G2. Supportive indexes add context and refine the picture but move less, or move for reasons other than age. The practical consequence is that if your primary indexes are unremarkable and a supportive index is at the edge of its range, the composite is unlikely to be telling you much. Read the primaries first.
Are my glycan index scores good or bad?
The indexes are reported against an age-matched and sex-matched reference range rather than against a universal target, so the comparison that matters is with people of your age and sex. There is no established treatment threshold, no clinical guideline that sets a cutoff, and no outcome trial that shows moving an index changes what happens to you. Treat the result as a description of your current inflammatory and immune state rather than as a number to be normalised.
Can the indexes tell me why my biological age is high?
Not on their own. The indexes describe the pattern rather than its cause, and the same elevated G0 can reflect an autoimmune condition, active inflammation, adiposity, smoking, hormonal state, or inherited variation. That is the reason a glycan result is more useful read against a standard panel than in isolation. hsCRP, fasting insulin, HbA1c, thyroid function and a lipid panel will identify a driver far more often than the glycan report will.
How quickly do the indexes change, and when is retesting worthwhile?
Age-related drift is slow. In longitudinal data, G0 rose about 15% over five years, which is roughly 3% a year, against an assay that reproduces to within 1 to 3%. A three-month retest is therefore measuring short-term inflammatory state rather than a change in ageing trajectory. In one study, 12 weeks produced no significant change in young men, and the changes seen in young women over the same window were attributed to menstrual cycle phase. If you retest, longer intervals and consistent cycle timing make the comparison interpretable.
How does a glycan test compare to a methylation clock?
They measure different biology and are not interchangeable. A methylation clock reads chemical tags on DNA and is usually trained to predict chronological age or mortality risk. A glycan test reads sugar structures on antibodies and is oriented toward chronic inflammation. Neither has an outcome trial showing that acting on the result improves health, and the two frequently disagree in the same person. Our comparison of the two families covers where each fits.
Related
- Best biological age test — five providers scored on one rubric
- Methylation clock vs immune age — the two families, and what each is built to detect
- How to read a biological age report — the general version of this guide
- What is biological age? — what the concept does and does not claim
- How to lower biological age — what the intervention evidence supports
- hsCRP — the inflammatory marker to read a glycan result against